Gavel Steve 4

What Happened
Steve Gavel, Chief Commercial Officer of Cabaletta Bio (CABA), made an open-market purchase of 22,170 shares on January 21, 2026. The filing reports a weighted average price of $2.27 per share, for a total transaction value of approximately $50,215. This was a purchase (insider buying), which investors often view as a mildly bullish signal, though motivations are not stated.

Key Details

• Transaction date: 2026-01-21. Report filed the same day (no late filing indicated).
• Price: weighted average $2.27; shares bought at prices in the range $2.26–$2.27 (footnote F1).
• Shares acquired: 22,170; total cash spent ≈ $50,215.
• Shares owned after transaction: not disclosed in the provided filing excerpt.
• Footnote F1: the reported price is a weighted average; the reporting person can provide a breakdown of how many shares were bought at each price in the $2.26–$2.27 range upon request.
• Transaction code: P (purchase / open-market).

Context
This was a modest-sized open-market buy (roughly $50k). Insider purchases can be informative, but a single small purchase doesn’t by itself prove a change in company prospects. The filing is factual and timely; it does not state any trading plan (e.g., 10b5-1) or other special circumstances.